Pretreatment serum albumin-to-alkaline phosphatase ratio is an independent prognosticator of survival in patients with metastatic gastric cancer
Yu-Ting Li, Xiao-Shu Zhou, Xiao-Ming Han, Jing Tian, You Qin, Tao Zhang, Jun-Li Liu
Yu-Ting Li, Xiao-Shu Zhou, You Qin, Tao Zhang, Jun-Li Liu, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China
Xiao-Ming Han, Department of Ultrasound Medicine, Jingmen Second People’s Hospital, Jingchu University of Technology Affiliated Central Hospital, Jingmen 448000, Hubei Province, China
Jing Tian, Department of Oncology, Hubei Cancer Hospital, The Seventh Clinical School Affiliated of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, Hubei Province, China
Author contributions: Liu JL, Tian J, Zhang T, and Li YT contributed to the study conception and design and data analysis; Zhou XS and Han XM collected the data; Li YT drafted the first version of the manuscript; Qin Y and Liu JL verified the data and edited the manuscript; The revision of the manuscript was performed by Zhang T and Tian J; The final version submitted for publication was critically reviewed and approved by all the authors.
Institutional review board statement: The study was approved by the Institutional Ethical Board of Wuhan Union Hospital of Tongji Medical College, Huazhong University of Science and Technology.
Informed consent statement: A waiver of informed consent was obtained for the study because this was a retrospective study, and anonymous analyses were employed in place to protect patient confidentiality, meaning there was minimal risk to the patients.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Jun-Li Liu, MD, PhD, Associate Chief Physician, Associate Professor, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jianghan Road, Wuhan 430022, Hubei Province, China. junli78@foxmail.com
Received: November 9, 2021
Peer-review started: November 9, 2021
First decision: December 12, 2021
Revised: December 26, 2021
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: May 15, 2022
